Navigation Links
miRagen announces discovery of key microRNA implicated in Lou Gehrig's disease
Date:12/11/2009

BOULDER, Colo., December 10, 2009 miRagen Therapeutics, Inc., a biopharmaceutical company focused on improving patients' lives by developing innovative microRNA-based therapeutics for cardiovascular and muscle disease, today announced the publication of data demonstrating that microRNA-206 (miR-206) plays a crucial role in the progression of amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease) and in neuromuscular synaptic regeneration in mice. The findings, published in the December 11 issue of the journal Science, reveal miR-206 as a potential target for the development of therapeutic agents for the treatment of neuromuscular disease. The study was conducted by researchers led by Eric N. Olson, Ph.D., at the University of Texas Southwestern Medical Center. miRagen is the exclusive licensee of intellectual property (IP) rights related to this discovery, which are part of the Company's extensive estate of enabled microRNA IP.

"This is a breakthrough with significant implications for human health," said William S. Marshall, Ph.D., President and CEO of miRagen Therapeutics, Inc. "Currently there are no therapies available to ALS patients that will reverse or delay the onset of muscle atrophy associated with this debilitating disease. Uncovering the essential role of miR-206 in neuromuscular maintenance brings us one step closer to the day when physicians will be able to offer hope to those suffering from ALS and other neuromuscular diseases."

"We are, quite frankly, excited by these findings," said Dr. Olson, Chairman and Professor of Molecular Biology at the University of Texas Southwestern Medical Center and miRagen's Chief Scientific Advisor. "One of the hallmarks of ALS and other similarly degenerative muscle diseases is the inability of the neuromuscular synapse to transmit the impulse that leads to muscle contraction. Our data show that miR-206 plays a central regulatory role in this process. We view this as an extremely promising target for therapeutic intervention."


'/>"/>

Contact: Tammy Egan
tegan@miragenrx.com
303-531-5952 x107
miRagen Therapeutics, Inc.
Source:Eurekalert  

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
3. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
4. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
5. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
6. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
7. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
8. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
9. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
10. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
11. CNS Response Announces Fiscal Third Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
miRagen announces discovery of key microRNA implicated in Lou Gehrig's disease
(Date:10/10/2017)... CALIF. (PRWEB) , ... October 10, 2017 , ... San ... part of its corporate rebranding initiative announced today. The bold new look is ... reach, as the company moves into a significant growth period. , It will also ...
(Date:10/10/2017)... ... 2017 , ... For the second time in three years, ... Award. Representatives of the FirstHand program travelled to Washington, D.C. Tuesday, October 10th, ... mission is to change the trajectory of STEM education in America by dramatically ...
(Date:10/10/2017)... DALLAS , Oct. 10, 2017 International research firm ... IoT Strategy, will speak at the TMA 2017 Annual Meeting , ... key trends in the residential home security market and how smart safety ... ... "The ...
(Date:10/10/2017)... , ... October 10, 2017 , ... ... and business process optimization firm for the life sciences and healthcare industries, announces ... conference in San Francisco. , The presentation, “Automating GxP Validation for Agile Cloud ...
Breaking Biology Technology:
(Date:4/4/2017)... , April 4, 2017   EyeLock LLC ... announced that the United States Patent and Trademark Office ... broadly covers the linking of an iris image with ... transaction) and represents the company,s 45 th issued ... patent is very timely given the multi-modal biometric capabilities ...
(Date:3/30/2017)... , March 30, 2017  On April 6-7, 2017, ... the Genome hackathon at Microsoft,s headquarters in ... competition will focus on developing health and wellness apps ... Hack the Genome is the first hackathon ... The world,s largest companies in the genomics, tech and ...
(Date:3/30/2017)... Trends, opportunities and forecast in this market ... (fingerprint, AFIS, iris recognition, facial recognition, hand geometry, vein ... use industry (government and law enforcement, commercial and retail, ... others), and by region ( North America ... Pacific , and the Rest of the World) ...
Breaking Biology News(10 mins):